With a Master's degree in Computer Science, Robin conducted research at the world's leading proteomics laboratory, the Yates lab, under the supervision of Dr. John Yates at The Scripps Research Institute for 16 years. During this time, he published over 50 scientific papers and two proteomics book chapters, in addition to giving numerous presentations at proteomics conferences. He is a former CEO and co-founder of Integrated Proteomics Applications, Inc., a bioinformatics company that was acquired by Bruker in 2020. He has also held positions as a director at both Bruker and The Scripps Research Institute.

Dr. Michael Lazear conducted research at the Cravatt lab under the supervision of Dr. Benjamin Cravatt at The Scripps Research Institute, renowned as the top-ranked institution (Nature Index) for biomedical research and a prestigious research institute in the United States. With over 15 years of experience in AI and bioinformatics, he has developed numerous innovative bioinformatics software. Dr. Lazear has been invited to speak at major conferences and was also recognized as a rising star by the Journal of Proteomics Research.

John R. Yates is the Ernest W. Hahn Professor in the Departments of Molecular Medicine & Neurobiology. His research interests include development of methods for tandem mass spectrometry analysis of protein mixtures, mass spectrometry bioinformatics using, & biological studies involving proteomics. He is the lead inventor of the SEQUEST software for correlating tandem mass spectrometry data to sequences in the database & developer of the shotgun proteomics technique for the analysis of protein mixtures. His laboratory has developed proteomic techniques to analyze protein complexes, posttranslational modifications, organelles & quantitative analysis of protein expression for the study of biology. He has received the ASMS Biemann Medal, HUPO Achievement Award, Christian Anfinsen Award (Protein Society), Analytical Chemistry award (ACS), Ralph N. Adams Award, Thomson Medal (IMSF), John B. Fenn Award (ASMS), HUPO Discovery Award. He is currently the EIC at the Journal of Proteome Research.

Jennifer Van Eyk, PhD, is an international leader in the area of clinical proteomics and her lab has focused on developing technical pipelines for de novo discovery and larger scale quantitative mass spectrometry methods. This includes multiple reaction monitoring (MRM, also known as SRM) and most recently data independent acquisition. Dr. Van Eyk's laboratory is well known for the extreme technical quality of the data generated, rigorous quality control with tight %CV while applying these to key clinical questions. The aim is to maximize throughput and reproducibility in order to move targeted and robust discovery methods into large population healthy continuous assessment and clinical grade assays focusing on brain and cardiovascular diseases.